Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Ezrin mediates c-Myc actions in prostate cancer cell invasion.

Chuan YC, Iglesias-Gato D, Fernandez-Perez L, Cedazo-Minguez A, Pang ST, Norstedt G, Pousette A, Flores-Morales A.

Oncogene. 2010 Mar 11;29(10):1531-42. doi: 10.1038/onc.2009.442. Epub 2009 Dec 14.

PMID:
20010876
2.

Epithelial-mesenchymal transitions in development and disease.

Thiery JP, Acloque H, Huang RY, Nieto MA.

Cell. 2009 Nov 25;139(5):871-90. doi: 10.1016/j.cell.2009.11.007. Review.

3.

The homeodomain protein HOXB13 regulates the cellular response to androgens.

Norris JD, Chang CY, Wittmann BM, Kunder RS, Cui H, Fan D, Joseph JD, McDonnell DP.

Mol Cell. 2009 Nov 13;36(3):405-16. doi: 10.1016/j.molcel.2009.10.020.

4.

Yurt, Coracle, Neurexin IV and the Na(+),K(+)-ATPase form a novel group of epithelial polarity proteins.

Laprise P, Lau KM, Harris KP, Silva-Gagliardi NF, Paul SM, Beronja S, Beitel GJ, McGlade CJ, Tepass U.

Nature. 2009 Jun 25;459(7250):1141-5. doi: 10.1038/nature08067.

PMID:
19553998
5.

ETS gene fusions in prostate cancer: from discovery to daily clinical practice.

Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA.

Eur Urol. 2009 Aug;56(2):275-86. doi: 10.1016/j.eururo.2009.04.036. Epub 2009 Apr 24. Review.

PMID:
19409690
6.

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP.

Nat Genet. 2009 May;41(5):619-24. doi: 10.1038/ng.370. Epub 2009 Apr 26.

7.

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.

King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL, Sawyers CL.

Nat Genet. 2009 May;41(5):524-6. doi: 10.1038/ng.371. Epub 2009 Apr 26.

8.

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.

Polyak K, Weinberg RA.

Nat Rev Cancer. 2009 Apr;9(4):265-73. doi: 10.1038/nrc2620. Epub 2009 Mar 5. Review.

PMID:
19262571
9.

Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.

Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M.

Cancer Res. 2008 Oct 15;68(20):8516-24. doi: 10.1158/0008-5472.CAN-08-1147.

10.

Recurrent gene fusions in prostate cancer.

Kumar-Sinha C, Tomlins SA, Chinnaiyan AM.

Nat Rev Cancer. 2008 Jul;8(7):497-511. doi: 10.1038/nrc2402. Epub 2008 Jun 19. Review.

11.

Potential role of EPB41L3 (protein 4.1B/Dal-1) as a target for treatment of advanced prostate cancer.

Bernkopf DB, Williams ED.

Expert Opin Ther Targets. 2008 Jul;12(7):845-53. doi: 10.1517/14728222.12.7.845 . Review.

PMID:
18554153
12.

Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer.

Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J.

Cancer Res. 2008 May 1;68(9):3094-8. doi: 10.1158/0008-5472.CAN-08-0198.

13.

Downregulation of several fibulin genes in prostate cancer.

Wlazlinski A, Engers R, Hoffmann MJ, Hader C, Jung V, Müller M, Schulz WA.

Prostate. 2007 Dec 1;67(16):1770-80.

PMID:
17929269
14.

Protein 4.1B suppresses prostate cancer progression and metastasis.

Wong SY, Haack H, Kissil JL, Barry M, Bronson RT, Shen SS, Whittaker CA, Crowley D, Hynes RO.

Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12784-9. Epub 2007 Jul 18.

15.

TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.

Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA.

Am J Surg Pathol. 2007 Jun;31(6):882-8.

PMID:
17527075
16.

Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer.

Schulz WA, Alexa A, Jung V, Hader C, Hoffmann MJ, Yamanaka M, Fritzsche S, Wlazlinski A, Müller M, Lengauer T, Engers R, Florl AR, Wullich B, Rahnenführer J.

Mol Cancer. 2007 Feb 5;6:14.

17.

Increased expression of the metastasis-associated gene Ehm2 in prostate cancer.

Wang J, Cai Y, Penland R, Chauhan S, Miesfeld RL, Ittmann M.

Prostate. 2006 Nov 1;66(15):1641-52.

PMID:
16927306
18.

Androgen induction of prostate cancer cell invasion is mediated by ezrin.

Chuan YC, Pang ST, Cedazo-Minguez A, Norstedt G, Pousette A, Flores-Morales A.

J Biol Chem. 2006 Oct 6;281(40):29938-48. Epub 2006 Jul 26.

19.

Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies.

Hoffmann MJ, Müller M, Engers R, Schulz WA.

Biochem Pharmacol. 2006 Nov 30;72(11):1577-88. Epub 2006 Jul 18.

PMID:
16854382
20.

Epigenetics of prostate cancer: beyond DNA methylation.

Schulz WA, Hatina J.

J Cell Mol Med. 2006 Jan-Mar;10(1):100-25. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk